Predictive
Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven
discovery services company that provides predictive models of tumor drug
response to improve clinical outcomes for patients, today announced the
extension of its secured promissory note. According to the update, the note’s
maturity date was extended from December 31, 2019 to March 31, 2020. In
addition, the outstanding principal amount of the note was increased by
$120,000 to a current principal amount of $2,029,104. Predictive Oncology
issued 15,000 shares of common stock to the investor in connection with certain
amended terms.
To view the full press release, visit http://ibn.fm/zyi8m
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through five
segments (Domestic, International, Clinical, CRO and DCHIP), which contain four
subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
Helomics applies artificial intelligence to its rich data gathered from patient
tumors to both personalize cancer therapies for patients and drive the
development of new targeted therapies in collaborations with pharmaceutical
companies. Helomics’ CLIA-certified lab provides clinical testing that assists
oncologists in individualizing patient treatment decisions, by providing an
evidence-based roadmap for therapy. In addition to its proprietary precision
oncology platform, Helomics offers boutique CRO services that leverage its
TruTumor(TM), patient-derived tumor models coupled to a wide range of
multi-omics assays (genomics, proteomics and biochemical), and an AI-powered
proprietary bioinformatics platform (D- CHIP) to provide a tailored solution to
its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is
developing a new rapid approach to growing tumors in the laboratory, which
essentially “fools” cancer cells into thinking they are still growing inside a
patient. Its proprietary Oncology Discovery Technology Platform kits will
assist researchers and clinicians to identify which cancer cells bind to
specific biomarkers. Once the biomarkers are identified they can be used in
TumorGenesis’ Oncology Capture Technology Platforms which isolate and help
categorize an individual patient’s heterogeneous tumor samples to enable the development
of patient specific treatment options. Helomics and TumorGenesis are focused on
ovarian cancer. Predictive Oncology’s Skyline Medical division markets its
patented and FDA cleared STREAMWAY System, which automates the collection,
measurement and disposal of waste fluid, including blood, irrigation fluid and
others, within a medical facility, through both domestic and international
divisions. The company has achieved sales in five of the seven continents
through both direct sales and distributor partners. For more information,
please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
